Therapeutic effect of targeted Fas-expressing adenoviruses method combining γδ T cells in a mouse model of human ovarian carcinoma

Zeng,Dingyuan; Lin,Jiajing; He,Hongying; Tan,Guangping; Lan,Ying; Jiang,Fuyan; Sheng,Shuting

doi:10.3892/ol.2017.7599

Therapeutic effect of targeted Fas-expressing adenoviruses method combining γδ T cells in a mouse model of human ovarian carcinoma

Authors:
- Dingyuan Zeng
- Jiajing Lin
- Hongying He
- Guangping Tan
- Ying Lan
- Fuyan Jiang
- Shuting Sheng
View Affiliations

Affiliations: Department of Oncology, Maternity and Children's Hospital Affiliated to the Guangxi University of Science and Technology, Liuzhou, Guangxi 545002, P.R. China, Department of Gynecology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Nanning 545000, P.R. China, Department of Gynecology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi 545002, P.R. China, Liuzhou Tumor Hospital, Liuzhou, Guangxi 545005, P.R. China, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545001, P.R. China
Published online on: December 13, 2017 https://doi.org/10.3892/ol.2017.7599
Pages: 2555-2561

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the therapeutic effect and safety of targeted use of Fas‑expressing adenoviruses combined with γδ T cell‑mediated killing to treat human ovarian cancer xenografts in BALB/c mice. Shuttle plasmids containing control elements of human telomerase reverse transcriptase promoter and two‑step transcriptional amplification system were constructed and packaged into adenovirus‑5 vectors to generate expression of an exogenous Fas gene. A mouse xenograft model of human ovarian carcinoma was constructed. A total of 35 BALB/c mice were randomly divided into five groups, which were injected with PBS, γδ T cells, Fas‑expressing adenoviruses, taxol, or Fas‑expressing adenovirus and γδ T cells. The weight and volume of tumors in mice in each group was monitored. Tissue sections of the various tissues of mice in the Fas‑expressing adenovirus and γδ T cells group was compared with those in the PBS group to evaluate the safety of Fas‑expressing adenovirus and γδ T cells in the treatment of human ovarian cancer xenograft tumors. The results of the present study indicated that mice in all treatment groups were alive at the end of the treatment course. Tumor weight and volume was the highest in the PBS group, followed successively by the adenovirus group, the γδ T cell group, the adenovirus and γδ T cell group, and the taxol group. The weight and volume inhibition rate in adenovirus and γδ T cell group were significantly higher compared with in the PBS group (P<0.05). Pathological observation of tissue samples revealed that none of vital organs in the adenovirus and γδ T cell group developed any evident morphological changes during treatment, when compared with healthy controls. In conclusion, the combined therapy with Fas‑expressing adenoviruses and γδ T cells is efficient and safe for the treatment of mouse human ovarian carcinoma xenografts.

View Figures

View References

1	Chen W, Delongchamps NB, Mao K, Beuvon F, Peyromaure M, Liu Z and Dinh-Xuan AT: High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncol Lett. 11:1375–1381. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ryu CJ, Whitehurst CE and Chen J: Expression of Gal4-VP16 and Gal4-DNA binding domain under the control of the T lymphocyte-specific lck proximal promoter in transgenic mice. BMB Rep. 41:575–580. 2008. View Article : Google Scholar : PubMed/NCBI
3	Yamashita Y: Ovarian cancer: New developments in clear cell carcinoma and hopes for targeted therapy. Jpn J Clin Oncol. 45:405–407. 2015. View Article : Google Scholar : PubMed/NCBI
4	Song Y, Xin X, Zhai X, Xia Z and Shen K: Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res. 7:1212014. View Article : Google Scholar : PubMed/NCBI
5	Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, et al: A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 8:2375–2382. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wu L, Johnson M and Sato M: Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med. 9:421–429. 2003. View Article : Google Scholar : PubMed/NCBI
7	Lin J, Zeng D, He H, Tan G, Lan Y, Jiang F and Sheng S: Gene therapy for human ovarian cancer cells using efficient expression of Fas gene combined with γδ T cells. Mol Med Rep. 16:3791–3798. 2017. View Article : Google Scholar : PubMed/NCBI
8	Song Y, Xin X, Xia Z, Zhai X and Shen K: Selective suppression of autocatalytic caspase-3 driven by two-step transcriptional amplified human telomerase reverse transcriptase promoter on ovarian carcinoma growth in vitro and in mice. Oncol Rep. 32:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
9	Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F and Miller G: A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA. 95:10866–10871. 1998. View Article : Google Scholar : PubMed/NCBI
10	Iyer M, Salazar FB, Lewis X, Zhang L, Wu L, Carey M and Gambhir SS: Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res. 14:47–55. 2005. View Article : Google Scholar : PubMed/NCBI
11	Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, et al: Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol. 46:77–88. 2007. View Article : Google Scholar : PubMed/NCBI
12	Guillermo LV, Silva EM, Ribeiro-Gomes FL, De Meis J, Pereira WF, Yagita H, DosReis GA and Lopes MF: The Fas death pathway controls coordinated expansions of type 1 CD8 and type 2 CD4 T cells in Trypanosoma cruzi infection. J Leukoc Biol. 81:942–951. 2007. View Article : Google Scholar : PubMed/NCBI
13	Brenes O, Arce F, Gätjens-Boniche O and Díaz C: Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. Biomed Pharmacoth. 61:347–355. 2007. View Article : Google Scholar
14	Collins M and Thrasher A: Gene therapy: Progress and predictions. Proc Biol Sci. 282:201430032015. View Article : Google Scholar : PubMed/NCBI
15	Naldini L: Gene therapy returns to centre stage. Nature. 526:351–360. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wang D and Gao G: State-of-the-art human gene therapy: Part II. Gene therapy strategies and clinical applications. Discov Med. 18:151–161. 2014.PubMed/NCBI
17	Hoshida H, Murakami N, Suzuki A, Tamura R, Asakawa J, Abdel-Banat BM, Nonklang S, Nakamura M and Akada R: Non-homologous end joining-mediated functional marker selection for DNA cloning in the yeast Kluyveromyces marxianus. Yeast. 31:29–46. 2014. View Article : Google Scholar : PubMed/NCBI
18	Mitsiades N, Yu WH, Poulaki V, Tsokos M and Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61:577–581. 2001.PubMed/NCBI
19	Villa-Morales M and Fernández-Piqueras J: Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:85–101. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhu HL, Wang YZ, Yu L, Li B, Yao SQ and Lou FD: The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 10:35–39. 2002.(In Chinese). PubMed/NCBI
21	Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA and Fang B: Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 62:3620–3625. 2002.PubMed/NCBI
22	Zhang Y, Ma H, Zhang J, Liu S, Liu Y and Zheng D: AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 82:1154–1161. 2008. View Article : Google Scholar : PubMed/NCBI
23	Iyer M, Wu L, Carey M, Wang Y, Smallwood A and Gambhir SS: Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA. 98:14595–14600. 2001. View Article : Google Scholar : PubMed/NCBI
24	Watanabe M, Ueki H, Ochiai K, Huang P, Kobayashi Y, Nasu Y, Sasaki K, Kaku H, Kashiwakura Y and Kumon H: Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging. Oncol Rep. 26:769–775. 2011.PubMed/NCBI
25	Merritt RE, Mahtabifard A, Yamada RE, Crystal RG and Korst RJ: Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg. 126:1609–1617. 2003. View Article : Google Scholar : PubMed/NCBI
26	Park IJ, Kim MJ, Park OJ, Park MG, Choe W, Kang I, Kim SS and Ha J: Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett. 298:88–98. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kanagawa N, Yanagawa T, Nakagawa T, Okada N and Nakagawa S: Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer Gene Ther. 20:57–64. 2013. View Article : Google Scholar : PubMed/NCBI
28	Habib HM, Taher TE, Isenberg DA and Mageed RA: Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha. Scand J Rheumatol. 38:112–120. 2009. View Article : Google Scholar : PubMed/NCBI
29	Xie J, Xiong L, Tao X, Li X, Su Y, Hou X and Shi H: Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma. Lung cancer. 68:338–345. 2010. View Article : Google Scholar : PubMed/NCBI
30	Matthews KS, Alvarez RD and Curiel DT: Advancements in adenoviral based virotherapy for ovarian cancer. Adv Drug Deliv Rev. 61:836–841. 2009. View Article : Google Scholar : PubMed/NCBI
31	Mahasreshti PJ, Kataram M, Wu H, Yalavarthy LP, Carey D, Fisher PB, Chada S, Alvarez RD, Haisma HJ, Dent P and Curiel DT: Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol. 100:521–532. 2006. View Article : Google Scholar : PubMed/NCBI